Arylacetamide κ opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 10, 2005, Pages 2647-2652

  Le Bourdonnec, Bertrand ^a   Ajello, Christopher W ^a   Seida, Pamela R ^a   Susnow, Roberta G ^a   Cassel, Joel A ^a   Belanger, Serge ^a   Stabley, Gabriel J ^a   DeHaven, Robert N ^a   DeHaven Hudkins, Diane L ^a   Dolle, Roland E ^a  

^a ADOLOR CORPORATION   (United States)

Author keywords

CYP2D6; Opioid

Indexed keywords

3,4 DICHLORO N METHYL N [1 PHENYL 2 (1 PYRROLIDINYL)ETHYL]BENZENEACETAMIDE; ACETAMIDE DERIVATIVE; CYTOCHROME P450 2D6; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR;

ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50;

EID: 20944445103     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.03.020     Document Type: Article

References (23)

1. A. Barber, and R. Gottschlich Exp. Opin. Invest. Drugs 6 1997 1351
2. J. Szmuszkovicz E. Jucker Progress in Drug Research Vol. 52 1999 Birkhauser Basel 167 195
3. J. Szmuszkovicz E. Jucker Progress in Drug Research Vol. 53 1999 Birkhauser Basel 1 51
4. G.F. Costello, B.G. Main, J.J. Barlow, J.A. Carroll, and J.S. Shaw Eur. J. Pharmacol. 151 1988 475
5. M. Eichelbaum, and A.S. Gross Pharmacol. Ther. 46 1990 377
6. Ajello, C. W.; Le Bourdonnec, B.; Cassel, J. A.; Stabley, G. J.; Belanger, S.; DeHaven, R. N.; Dolle, R. E. Abstracts of Papers, 228th National Meeting of the American Chemical Society, Philadelphia, PA, Sept 22-26, 2004; MEDI 46
7. S. Ekins, M.J. de Groot, and J.P. Jones Drug Metab. Dispos. 29 2001 936
8. D.A. Smith, M.J. Ackland, and B.C. Jones Drug Discovery Today 2 1997 406
9. D.A. Smith, M.J. Ackland, and B.C. Jones Drug Discovery Today 2 1997 479
10. A.S. Kalgutkar, S. Zhou, O.A. Fahmi, and T.J. Taylor Drug Metab. Dispos. 31 2003 596
11. P.A. Williams, J. Cosme, V. Sridhar, E.F. Johnson, and D.E. McRee Mol. Cell 5 2000 121
12. MOE (Molecular Operating Environment), version 2002.03; Chemical Computing Group, Inc., Montreal, Quebec, Canada
13. GLIDE, version 2.5, Shrodinger, Inc., Portland, Oregon, USA
14. G. Subramanian, M.G. Paterlini, D.L. Larson, P.S. Portoghese, and D.M. Ferguson J. Med. Chem. 41 1998 4777
15. V. Kumar, M.A. Marella, L. Cortes-Burgos, A.-C. Chang, J.A. Cassel, J.D. Daubert, R.N. DeHaven, D.L. DeHaven-Hudkins, S.L. Gottshall, E. Mansson, and A.L. Maycock Bioorg. Med. Chem. Lett. 10 2000 2567
16. G.F. Costello, R. James, J.S. Shaw, A.M. Slater, and N.C.J. Stutchbury J. Med. Chem. 34 1991 181
17. R. Gottschlich, K.A. Ackermann, A. Barber, G.D. Bartoszyk, and H.E. Greiner Bioorg. Med. Chem. Lett. 4 1994 677
18. Yatsunami, T.; Yazaki, A.; Inoue, S.; Yamamoto, H.; Yokomoto, M.; Nomiyama, J.; Noda, S. European Patent 0,343,560, 1989
19. For a full description of the biological methods, see: G. Schlechtingen, R.N. DeHaven, J.D. Daubert, J.A. Cassel, N.N. Chung, P.W. Schiller, J.P. Taulane, and M. Goodman Structure-activity relationships of dynorphin A analogs modified in the address sequence J. Med. Chem. 46 2003 2104
20. N. Chauret, B. Dobbs, R.L. Lackman, K. Bateman, D.A. Nicoll-Griffith, D.M. Stresser, J.M. Ackermann, S.D. Turner, V.P. Miller, and C.L. Crespi Drug Metab. Dispos. 29 2001 1196
21. 50 for ICI 199441 was measured after pre-incubation for 30 min with CYP2D6, suggesting that the compound is a substrate for the enzyme (unpublished observation)
22. For a recent review, see: R. Pearlstein, R. Vaz, and D. Rampe J. Med. Chem. 46 2003 2017
23. In vivo test methods; acetic acid-induced writhing: mice were treated with vehicle or compound 13 and 15 min later injected with 0.6% acetic acid intraperitoneally. Five minutes after the administration of acetic acid, the number of writhes was counted for a 10 min period